Literature DB >> 16103877

Rituximab (chimeric anti-CD20) sensitizes B-NHL cell lines to Fas-induced apoptosis.

Mario I Vega1, Sara Huerta-Yepez, Ali R Jazirehi, Hermes Garban, Benjamin Bonavida.   

Abstract

Rituximab (chimeric anti-CD20 monoclonal antibodies) is currently being used in the treatment of B non-Hodgkin's lymphoma (NHL). We have recently reported that rituximab triggers and modifies various intracellular signaling pathways in NHL B-cell lines, resulting in reverting the chemoresistant phenotype to a sensitive phenotype. This study investigated whether rituximab also modifies intracellular signaling pathways resulting in the sensitization of NHL cells to Fas-induced apoptosis. Treatment of the Fas-resistant NHL cell lines (2F7, Ramos and Raji) with rituximab sensitized the cells to CH-11 (FasL agonist mAb)-induced apoptosis and synergy was achieved. Fas expression was upregulated by rituximab as early as 6 h post-treatment as determined by flow cytometry, reverse transcriptase-polymerase chain reaction and Western blot. Rituximab inhibited both the expression and activity of the transcription repressor Yin-Yang 1 (YY1) that negatively regulates Fas transcription. Inhibition of YY1 resulted in the upregulation of Fas expression and sensitization of the tumor cells to CH-11-induced apoptosis. The downregulation of YY1 expression was the result of rituximab-induced inhibition of both the p38 mitogen-activated protein kinase (MAPK) signaling pathway and constitutive nuclear factor kappa of B cells (NF-kappaB) activity. The involvement of NF-kappaB and YY1 in the regulation of Fas expression was corroborated by the use of Ramos cells with a dominant-active inhibitor of NF-kappaB (Ramos IkappaB-estrogen receptor (ER) mutant) and by silencing YY1 with YY1 siRNA, respectively. Further, the role of rituximab-mediated inhibition of the p38 MAPK/NF-kappaB/YY1 pathway in the regulation of Fas and sensitization to CH-11-induced apoptosis was validated by the use of specific chemical inhibitors of this pathway and which mimicked rituximab-mediated effects. These findings provide a novel mechanism of rituximab-mediated activity by sensitizing NHL cells to Fas-induced apoptosis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16103877     DOI: 10.1038/sj.onc.1208954

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  33 in total

Review 1.  Anti-CD20 Directed Therapy of B Cell Lymphomas: Are New Agents Really Better?

Authors:  Ciara L Freeman; Laurie Sehn
Journal:  Curr Oncol Rep       Date:  2018-11-27       Impact factor: 5.075

2.  Multiple signaling pathways induced by hexavalent, monospecific, anti-CD20 and hexavalent, bispecific, anti-CD20/CD22 humanized antibodies correlate with enhanced toxicity to B-cell lymphomas and leukemias.

Authors:  Pankaj Gupta; David M Goldenberg; Edmund A Rossi; Chien-Hsing Chang
Journal:  Blood       Date:  2010-07-13       Impact factor: 22.113

Review 3.  Rituximab: as first-line maintenance therapy following rituximab-containing therapy for follicular lymphoma.

Authors:  Jamie D Croxtall
Journal:  Drugs       Date:  2011-05-07       Impact factor: 9.546

Review 4.  Mechanisms of Yin Yang 1 in oncogenesis: the importance of indirect effects.

Authors:  Michael Atchison; Arindam Basu; Kristina Zaprazna; Madhusudhan Papasani
Journal:  Crit Rev Oncog       Date:  2011

Review 5.  The oncogenic role of Yin Yang 1.

Authors:  Qiang Zhang; Daniel B Stovall; Kazushi Inoue; Guangchao Sui
Journal:  Crit Rev Oncog       Date:  2011

6.  Transcription regulator Yin-yang 1: from silence to cancer.

Authors:  Weidong Zhu; Samuel Y Olson; Hermes Garbán
Journal:  Crit Rev Oncog       Date:  2011

7.  Inhibition of p38 MAPK activity in B-NHL Raji cells by treatment with engineered CD20-specific T cells.

Authors:  Lei Jiang; Kang Yu; Jimei DU; Wuhua Ni; Yixiang Han; Shenmeng Gao; Haiying Li; Jianbo Wu; Yihu Zheng; Yingxia Tan
Journal:  Oncol Lett       Date:  2011-05-13       Impact factor: 2.967

8.  Epstein-Barr virus in bone marrow of rheumatoid arthritis patients predicts response to rituximab treatment.

Authors:  Mattias Magnusson; Mikael Brisslert; Kiandoht Zendjanchi; Magnus Lindh; Maria I Bokarewa
Journal:  Rheumatology (Oxford)       Date:  2010-06-14       Impact factor: 7.580

9.  Mechanism of Fas signaling regulation by human herpesvirus 8 K1 oncoprotein.

Authors:  Zuzana Berkova; Shu Wang; Jillian F Wise; Hoyoung Maeng; Yuan Ji; Felipe Samaniego
Journal:  J Natl Cancer Inst       Date:  2009-03-10       Impact factor: 13.506

10.  Receptor-interacting protein shuttles between cell death and survival signaling pathways.

Authors:  Pachiyappan Kamarajan; Julius Bunek; Yong Lin; Gabriel Nunez; Yvonne L Kapila
Journal:  Mol Biol Cell       Date:  2009-12-02       Impact factor: 4.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.